Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Yarrow Bioscience, Inc./ 10-K

Annual Report · 10-K

Yarrow Bioscience, Inc.

Annual Report

Filed Feb 27, 2026Accepted Feb 27, 2026, 8:01 AM ESTCIK 1566044Accession 0001566044-26-000002
View company →Permanent SEC source ↗
Share

Company context

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (“TSHR”) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED. For more information, visit www.yarrowbioscience.com.

Current securities

YARWNASDAQ · EQUITY · Current
Historical securities (1)
VYNENASDAQ · EQUITY · Historical · closed Jul 27, 2026

Recent company filings

  1. Entry into a Material Definitive AgreementSep 14, 2026
  2. 424B5 filingSep 11, 2026
  3. 424B5 filingSep 11, 2026
  4. Other EventsSep 10, 2026
  5. EFFECT filingAug 19, 2026

Registered securities in this filing

VYNE THERAPEUTICS INC. · 10-K · Filed 2026-02-27

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001

Symbol
VYNE
Exchange
NASDAQ
Classification
COMMON
Status
Historical · closed Jul 27, 2026
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000156604426000002 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.